ACTRN12607000082404Not yet recruitingPhase 2
A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomy
rology Department The Royal Melbourne Hospital0 sites15 target enrollmentStarted: January 24, 2007Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- Male
Inclusion Criteria
- •Provision of written informed consent, Prostate cancer confirmed by biopsy within 6 weeks prior to consent. At least one of the following: PSA level > 15 g/L, Gleason score > 8, Clinical stage T2b or T3 disease at study entry. >50% of positive coresConsidered suitable for radical prostatectomy
Exclusion Criteria
- •Evidence of metastatic diseasePrior cytotoxic chemotherapy.Prior hormone therapy.Treatment with an investigational agent in the last 4 weeks.Other co-existing malignancies or malignancies diagnosed within the last 2 years with the exception of non-melanoma skin cancer.Incomplete healing from previous surgery.Absolute neutrophil count (ANC) < 1 x 109/L or platelets < 100 x 109/L.Serum bilirubin > 1.25 times the upper limit of reference range (ULRR).Initial serum creatinine 1.5 times the ULN and/or calculated creatinine clearance (by Cockroft-Gault Formula) <60 ml/min and/or known progressive renal disease. ALT or AST > 2.5 times the ULRR.Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.Recent (within 6 weeks) or planned dental or jaw surgery (e.g.extraction, implants)In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease).Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.
Investigators
Similar Trials
Recruiting
Not Applicable
A pilot study of psychotherapeutic intervention for complex presentations of first-episode psychosisEarly psychosisMental Health - Psychosis and personality disordersBorderline Personality DisorderACTRN12605000594628Orygen Research Centre and Orygen Youth Health16
Recruiting
Phase 1
A pilot study of patients with oligometastases from breast cancer treated with stereotactic ablative body radiosurgery in combination with the anti-PD-1 antibody MK-3475.Metastatic Breast Cancer (1-5 metastases)Cancer - BreastCancer - BoneACTRN12614001181695Peter MacCallum Cancer Centre15
Recruiting
Not Applicable
A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using Indocyanine green.NL-OMON24349Meander Medical Centre, Department of Surgery10
Active, not recruiting
Phase 1
Identification of the sentinel lymph node (SLN) in patients with colon carcinoma.Colon carcinomaEUCTR2021-006796-41-NLMeander Medical Centre5
Completed
Not Applicable
A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CWcolon carcinomaintestinal cancer1001799010017991NL-OMON53524Meander Medisch Centrum5